Because non-small cell lung cancer (NSCLC) constitutes 85% of lung cancer [13], the aim of this study was to explore the clinical prediction of TFPI-1 for NSCLC patients with DVT and tumor metastasis. Here, TFPI is linked to non-small cell lung carcinoma.